Multicenter Trial for Adults With Partial Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00034814
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : March 17, 2011
Information provided by:
Teva Pharmaceutical Industries

Brief Summary:
To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Talampanel Drug: Placebo Phase 2

Detailed Description:
A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 190 participants
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.
Study Start Date : January 2002
Actual Primary Completion Date : January 2006
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 1
Enzyme-inducing placebo TID
Drug: Placebo
Enzyme-inducing placebo TID
Experimental: 2
Enzyme-inducing Talampanel 35 mg TID
Drug: Talampanel
Enzyme-inducing Talampanel 35 mg TID
Experimental: 3
Enzyme-inducing TLP 50mg TID
Drug: Talampanel
Enzyme-inducing TLP 50mg TID
Placebo Comparator: 4
Non-enzyme-inducing placebo TID
Drug: Placebo
Non-enzyme-inducing placebo TID
Experimental: 5
Non-enzyme-inducing TLP 25mg TID
Drug: Talampanel
Non-enzyme-inducing TLP 25mg TID
Experimental: 6
Non-enzyme-inducing TLP 35mg TID
Drug: Talampanel
Non-enzyme-inducing TLP 35mg TID

Primary Outcome Measures :
  1. Reduction in frequency of partial seizures [ Time Frame: 12 weeks ]
    Change in frequency of recognizable seizures as measured by entries in a seizure diary

Secondary Outcome Measures :
  1. The number of seizure-free days and percent responders [ Time Frame: 12 weeks ]
    A responder was defined as a patient with greater than or equal to 50% reduction in seizure frequency compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must weigh greater than or equal to 40kg
  • Patients must have diagnosis of partial seizures
  • At least 3 observable partial seizures a month
  • Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.


  • Patients on Valproic acid, and Felbamate

Responsible Party: Siyu Liu, Vice President, North American IR&D and Head of Global Clinical Operations, Teva Branded Pharmaceutical Products R&D, Inc. Identifier: NCT00034814     History of Changes
Other Study ID Numbers: IXL-201-14-189
First Posted: May 3, 2002    Key Record Dates
Last Update Posted: March 17, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms